Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 30;61(9):e270-e273.
doi: 10.1093/rheumatology/keac276.

Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis

Muhammad R A Shipa  1 , Lawrence Langley  2 , Benjamin Sacks  2 , Su-Ann Yeoh  1 , M D Mainuddin  3 , Dev Mukerjee  3 , Madhura Castelino  1 , Michael R Ehrenstein  1
Affiliations

Increased erythrocyte mean corpuscular volume by methotrexate predicts clinical response in psoriatic arthritis

Muhammad R A Shipa et al. Rheumatology (Oxford). .
No abstract available

PubMed Disclaimer

Figures

<sc>Fig</sc>. 1
Fig. 1
Longitudinal change in erythrocyte mean corpuscular volume from baseline to predict response to MTX at 24 weeks in PsA (A) Longitudinal change in MCV from baseline through to 24 weeks, stratified by their response at 24 weeks. Longitudinal linear mixed-effect model was fitted with random effect of individual patient and fixed effect of response intercepting with observation times between baseline and week 24 and adjusted for screening MCV values, age, gender, concomitant conventional synthetic DMARDs, MTX dose, and haemoglobin at each time point. Estimated mean with 95% CIs and number of patients at each time points (N) are shown. (B) Area under the receiver operator characteristic (ROC) curve (AUROC) of MCV change (from baseline) at each time point to predict response at 24 weeks. (C) Sparse partial least squares discriminant analysis (sPLS-DA). Factor-loading weights in component 1 are shown for the top five ranked parameters that predict MTX response. (D) Multiple logistic regression with the parameters chosen by sPLS-DA to construct the final model to predict MTX response at 24 weeks. *For each 1 fL increase in MCV. (E) Number and percentage of the patients who achieved the clinical response by 24 weeks, stratified by increase in MCV ≥3.9 fL from baseline and PsARC response at 12 weeks. Pairwise comparison was made by Fisher’s exact test. Response at 24 weeks was defined as an improvement in at least two of the four PsA response criteria (PsARC), one of which must be related to joint tenderness or swelling, with no worsening in any of the four criteria by 24 weeks and no initiation of additional conventional synthetic DMARDs or biologics within the 52 weeks of MTX initiation. Response at 12 weeks was defined as an improvement in at least two of the four PsA response criteria (PsARC), one of which must be related to joint tenderness or swelling, with no worsening in any of the four criteria by 12 weeks. MCV: mean corpuscular volume; OD: odds ratio.
See this image and copyright information in PMC

References

    1. Shipa MRA, Yeoh S-A, Embleton-Thirsk A, Mukerjee D, Ehrenstein MR.. The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume. Rheumatology 2022;61:787–93. - PMC - PubMed
    1. Taylor W, Gladman D, Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665–73. - PubMed
    1. Mease PJ, Antoni CE, Gladman DD, Taylor WJ.. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64:ii49–54. - PMC - PubMed
    1. Kingsley GH, Kowalczyk A, Taylor H. et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology 2012;51:1368–77. - PMC - PubMed
    1. van der Heijde D, Ramiro S, Landewé R. et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91. - PubMed

Publication types